S Sc School; 5 5 De De D pt pt pt o o of f Pa Pa Path th thol ol olog og o y, y, y, B B Bri ri righ gh gha a am m m an an and d d Wo W W me me m n's s s Ho Ho Hosp sp spital al al; 6 6 6 De De D pt pt pt o o of Pa Pa ath th thol ol olog og ogy, y, , H H Har ar arva va vard rd r Abstract Background-Experience with aortic valve replacement (AVR) using current-generation pericardial bioprostheses in young patients is limited. The death of a child with accelerated bioprosthetic aortic stenosis prompted enhanced surveillance of all such patients at our institution. Methods and Results-We reviewed records of 27 patients who had undergone AVR (median follow-up 13.7 months) with a bovine pericardial bioprosthesis at age 30 years. In the Mitroflow® LXA valve group (n=15), freedom from valve failure was 100% at 1 year, 53% (95% confidence interval [CI] 12-82%) at 2 years, and 18% (CI 1-53%) at 3 years. No Magna®/Magna Ease® valves (n=12) failed by 3 years. Among valve failure patients, median age at AVR was 12 years (range 10-21 years). Life-threatening prosthetic aortic stenosis was detected at a median of 6 months following prior echocardiograms showing mild gradients. Patients with Mitroflow® LXA compared to Magna®/Magna Ease® valves were smaller (median BSA 1.42 vs. 1.93, p=0.002) and younger (median 13.0 vs. 20.9 years, p=0.02) at AVR. Pathology demonstrated diffuse intrinsic leaflet calcification, unassociated with inflammation or infection, and virtually immobile leaflets in closed position. Conclusions-Young patients undergoing AVR with Mitroflow® LXA pericardial valves are at high risk for rapid progression from mild to severe aortic stenosis over months, highlighting their need for heightened echocardiographic surveillance and suggesting that this aortic bioprosthesis should not be implanted in the young. Current data are insufficient to assess the safety of AVR with other pericardial bioprostheses in children and the youngest adults. Key words: heart defects, congenital, prosthetic valve 95% confidence interval [CI] 12-82%) at 2 years, and 18% (CI 1-53%) at 3 yea ar r rs. No No No Magna®/Magna Ease® valves (n=12) failed by 3 years. Among valve failure patients, median ag ge e e at at at A A AVR VR VR w w was s 1 1 12 2 2 years (range 10-21 years). L L Lif if i e e-threatening p p pro ro r sthe he heti ti tic c aortic stenosis was d de dete e ec cted at a me medi d d a an an o o of 6 6 6 m m mon on ont th ths s fo fo foll llo ow wi ing pr r rior f ec c cho oca ca card rdi io i g gr gram am ms s s sh sh ho ow owin ing g g m mil il ld d gr gr g ad ad a ie ie ient nt ts s. Pa Pati ti tien en nts ts t w wit it ith h h Mi Mit tro of oflo lo ow® w® ® LXA XA XA c c com om ompa pa are re ed d d to to to M M Mag ag gn na a® ®/ ®/Ma Ma Mag gn gna a a Ea Ea ase se e® ® ® v v val lv lves es s w w wer ere e e sm sm smal al lle e er r median BSA A 1. 1. .42 42 2 vs vs v . . 1 1 1.9 . 3, 3, 3, p p p=0 =0 0.0 .0 .002 02 2) ) an an and d d yo yo youn un unge ge ger r r (m (m med d dia ia ian n n 13 13 13.0 .0 .0 vs vs s. .
Introduction
A 13 year old girl who had undergone implantation of a bovine pericardial bioprosthesis (Mitroflow® LXA) in the aortic position at our institution died suddenly 23 months later during a severe gastrointestinal illness. Postmortem examination showed severe bioprosthetic valve obstruction and left ventricular hypertrophy. An echocardiogram 7 months earlier had demonstrated only mild stenosis and decreased mobility of a single leaflet. Intensified echocardiographic surveillance in response to this sentinel event revealed rapid onset structural valve deterioration, manifest as severe prosthetic valve stenosis, in other asymptomatic children and young adults. The apparent rapid appearance of structural valve deterioration with this bovine pericardial valve in asymptomatic patients prompted an alert to professional cardiovascular societies and publication of the information by the U.S. Food and Drug Administration in a MedSun newsletter. 1 We report our experience of early failure with the Mitroflow® LXA pericardial bioprosthetic valve in the aortic position in patients who were 30 years of age at implantation.
Our review describes rapid onset and potentially life-threatening valve failure in young patients with a Mitroflow® LXA aortic prosthesis, with progression from mild to severe aortic stenosis over a period of months.
Methods

Patient Selection
We reviewed the records of all patients who were 30 years old at the time of aortic valve replacement (AVR) with a bovine pericardial bioprosthetic valve at a single institution.
Pericardial tissue valves were implanted in the aortic position from March 2009 through April bovine pericardial valve in asymptomatic patients prompted an alert to profession on nal al l cardiovascular societies and publication of the information by the U.S. Food and Drug Ad Admi mi mini ni ni t st stra ra rati ti tio o on i in n n a a a MedSun newsletter. 1 We rep por or rt ou our r ex ex xpe pe eri ri rien en ence 
Data Obtained from Chart Review
Anthropometric data, clinical history, prior aortic valve procedures, and indications for surgery were ascertained by retrospective chart review. Valve failure was defined as reoperation or sudden death resulting from structural valve deterioration.
Echocardiogram Review
Digitally archived echocardiograms were reviewed by a single experienced echocardiographer (TG) in random order without knowledge of valve type or patient outcome. Echocardiograms http://circ.ahajournals.org/ Downloaded from restriction of 2 or 3 leaflets. Aortic leaflet thickness was graded as: 1) normal; 2) mild thickening (leaflet thickness < aortic root wall thickness) of 1 leaflet; 3) moderate or severe thickening (leaflet thickness aortic root wall thickness) of 1 leaflet; or 4) moderate or severe thickening of 2 or more leaflets. Structural valve deterioration is defined as an alteration in the leaflet thickness or mobility score from normal, with or without resultant aortic stenosis or regurgitation.
Echocardiographic image quality was scored as 1) non-diagnostic; 2) adequate; 3) good; or 4) excellent.
Pathology
Four bioprosthetic aortic valves were available for examination, 1 at autopsy and 3 after explantation for severe valve stenosis. Valves were examined and photographed in the fresh state when possible. The valves were fixed in 10% neutral buffered formalin. One or 2 sections from the free edge to the base of selected leaflets were processed for histology, embedded in paraffin, cut into 5 m sections, mounted and stained with hematoxylin and eosin. Von Kossa and Mason trichrome stains were also performed in selected cases.
Three valves underwent computed tomographic (CT) imaging using a 64-detector scanner (Sensation 64; Siemens, Erlangen, Germany) (120 kV, 140 mas, 0.6 mm slice thickness) yielding a 3D data set (voxel size 0.33 x 0.33 x 0.6 mm). The CT images were reviewed on a Fuji Synapse work station (Fujifilm Medical Systems, Stamford, CT, USA) and 3D reconstructions of the data sets were created using Voxar software (Voxar, Toshiba). Images were reviewed as raw images, after reformatting in maximum intensity projection (MIP) mode, and as 3D volumetric reconstructions. The 3D volumetric images were segmented automatically with Voxar software using a threshold for calcium density that maximized the differentiation between calcified and uncalcified leaflet tissue. explantation for severe valve stenosis. Valves were examined and photographed d i i in th th t e e e fr fr fres es esh h h st state when possible. The valves were fixed in 10% neutral buffered formalin. One or 2 sections from h he e fr fr free ee ee e edg dg dge e to t t the he he b base of selected leaflets wer re e e pr pr rocessed for hi hist s s olog og gy y, y, embedded in paraffin, cu ut in into 5 m se sec ct c i i ions ns s, , mo mo moun un unte te ed d an an and d d st tai ined d d w w with h hem ema at ato ox oxy y yli in n a and nd nd e eos osin in. . Vo Vo Von n n Ko Ko oss ssa a a a an nd d d Ma Ma Mas so son r ric ic chr hr hrom om ome e st st stai a ains ns w wer ere e al also so pe e erf rf for or orme me med d i in in s s sel el ele e ecte te ted d ca ca cas ses s s.
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Statistical Analysis
Descriptive statistics were used to characterize the cohorts of patients implanted with the Review of echocardiograms disclosed structural valve deterioration similar to that seen just prior to onset of severe prosthetic aortic valve stenosis in 3 additional patients (# 5, 9, and 10) with Mitroflow® LXA valves at 13, 19, and 19 months after AVR (Figure 5) . In all patients,
Echocardiographic findings
Echocardiograms were performed 6, 6, 9, and 3 months prior to discovery of severe prosthetic 
Comparison between valve types
Patient and valve characteristics at the time of placement and at latest follow up were compared between Mitroflow® LXA and Magna®/Magna Ease® valve groups ( In analyses within the Mitroflow® group, patients with valves that failed, compared with those with valves that to date remain in situ, had longer duration of follow-up (median 20.2 versus 13.4 months, respectively, p=0.05). No baseline patient factor or valve characteristic was found to be associated with valve failure within the Mitroflow® group.
Co Comp mp mpa ar aris is ison on o bet et tw we ween valve types
Gross pathology, CT, and histology of failed valves
In 3 of 4 cases (patients #11, 12, and 13), the valve leaflets were firm and stiff with little or no mobility. Only a 2-3 mm rim of leaflet tissue at the free edge was pliable. The leaflets were virtually fixed in a nearly closed (diastolic) position, leaving only a small effective valve orifice (Figure 1) . The valve leaflets were densely and diffusely calcified, particularly in the belly and around the commissures, and extremely stiff (Figure 6, Movie 1) . The free edges of the leaflets were less calcified but were often thickened and showed delamination. Calcific nodules were present on some leaflets and around commissures. The fourth valve (patient 8) was less affected.
Only 1 leaflet was densely calcified and fixed. An adjacent leaflet was moderately calcified with reduced mobility. The third leaflet was not calcified by gross inspection with near normal mobility. Mild tissue overgrowth (pannus) was present around the sewing ring and base of some leaflets. Tiny thrombi (< 1 mm) were present on the ventricular surface at the commissures in 1 case. No leaflet tear was seen and there was no evidence of endocarditis.
Maximum intensity projection and 3D volumetric images of the reformatted CT data sets showed calcium density predominantly in the leaflet belly, with variable extension toward the free edge and around the commissures (Figure 6, Movie 2) . Calcium density was largely mobility. Only a 2-3 mm rim of leaflet tissue at the free edge was pliable. The lea ea afl flet et e s s we we were re re virtually fixed in a nearly closed (diastolic) position, leaving only a small effective valve orifice Aortic valve replacement is performed in children when valve repair is not possible or when a previously repaired valve deteriorates. Options for a replacement valve include mechanical prostheses, homografts, autologous tissue valves (Ross procedure), or bioprosthetic valves, the latter reported in early studies to have abbreviated graft life in children. 10, 11 In the current era, however, newer bioprosthetic aortic valves, including pericardial valves, have had improved durability in older patients, shifting preference towards their use. [12] [13] [14] Strong desire by patients and families to avoid anticoagulation and associated complications and/or life-style modifications has furthered the interest in use of bioprosthetic valves. Concerns about long-term neo-aortic root dilation and potential need for reoperation on both the neo-aortic and the replaced pulmonary valve have reduced the attractiveness of the Ross procedure. 15, 16 Pericardial valves are often implanted in the pulmonary position in children and young adults with tetralogy of Fallot, some of whom have high pulmonary artery pressure, with reasonable durability. 17, 18 Moreover, enthusiasm for bioprosthetic aortic valve replacement has risen with the prospect of valve-in-valve technology, 19, 20 which could reduce the number of anticipated surgical valve rereplacements. However, the acuity of calcification and resultant critical stenosis of the when a previously repaired valve deteriorates. Options for a replacement valve in in ncl lud ud ude e mechanical prostheses, homografts, autologous tissue valves (Ross procedure), or bioprosthetic va alv lv ves es s, , th th the e e la la lat tter r r r re ep eported in early studies to have ve ve ab b bbreviated gra aft ft f lif fe e e in in in children. 10, 11 In the Mitroflow® LXA valve in our series of children and very young adults greatly outweigh the potential benefits or rationale for its implantation. These data highlight the need for more research and development focused on valve replacement in the young.
Curves depicting time to reoperation after aortic bioprosthetic valve replacement in adults are nonlinear, with an inflection point that occurs approximately 6-10 years after AVR. 9, [21] [22] [23] [24] [25] [26] Few data are available, however, to describe the rate of progression of stenosis in the individual patient. In a longitudinal analysis of serial echocardiographic measurements after aortic valve replacement in children, Karamlou et al. 27 reported an initial rapid rise in prosthetic aortic valve gradient, followed by a more gradual rise. Their findings, which included only a minority of patients with pericardial aortic bioprostheses, contrast with our observation of a stable period of minimal stenosis, followed by a sharp rise in gradient.
In our series, the mechanism of bioprosthetic valve failure was intrinsic calcification of thickened valve leaflets that became stiffened, immobile, and ultimately fixed in diastolic position, dramatically reducing effective orifice area and causing severe aortic stenosis.
Although minimal pannus overgrowth of the base of leaflets was observed in some cases, this did not appear to be an important mechanism for dysfunction. No leaflet was torn or otherwise disrupted, consistent with the minimal aortic insufficiency observed clinically. The calcification process did not involve host cells and was not associated with inflammation or infection. Our report has several limitations. We retrospectively reviewed a small series of patients of varying ages, growth potential, and underlying congenital heart disease. Valve failure events were few in number, though proportionally high, and some potential risk factors were collinear.
Previous reports on mechanisms of deterioration of the
The current report did not analyze risk factors for bioprosthetic valve deterioration related to valve design or valve production. The Magna® and Magna Ease® valves are fabricated using a proprietary ThermaFix® process aimed at reducing leaflet calcification. Of note, the absence of anti-mineralization treatment in some bioprosthetic valves, including the Mitroflow® LXA, has been shown to be an independent predictor of structural valve deterioration in one prior report. 21 The relationship between the use of this process and the observed lower incidence of early leaflet calcification and immobility in patients receiving the Magna® and Magna Ease® valve is speculative, although supported by other published data. 17 
